keyword
MENU ▼
Read by QxMD icon Read
search

Oncology and hematology

keyword
https://www.readbyqxmd.com/read/29042833/impact-of-a-pharmacist-led-chemotherapy-education-program-on-the-knowledge-of-pediatric-hematology-oncology-nurses
#1
Christine M Fisher, Abby J Kim, Joshua J Elder
OBJECTIVES: Medication errors involving chemotherapy are a serious source of avoidable medical harm that can result in chemotherapy-related adverse drug events. Efforts to reduce errors in the past decade have largely focused on chemotherapy errors at the prescriber level, using computerized or automated technology, but little has been done to ensure chemotherapy is administered accurately at the nursing level. The current study implemented a pharmacist-led, supplemental, institution-specific training program to nursing staff regarding the use of chemotherapy and to address knowledge deficits in newly hired nursing personnel...
September 2017: Journal of Pediatric Pharmacology and Therapeutics: JPPT: the Official Journal of PPAG
https://www.readbyqxmd.com/read/29037236/a-single-arm-phase-ii-study-of-nab-paclitaxel-for-patients-with-chemorefractory-non-small-cell-lung-cancer
#2
Hisashi Tanaka, Kageaki Taima, Takeshi Morimoto, Yoshihito Tanaka, Masamichi Itoga, Kunihiko Nakamura, Akihito Hayashi, Mika Kumagai, Hideo Yasugahira, Megumi Mikuniya, Koichi Okudera, Shingo Takanashi, Sadatomo Tasaka
BACKGROUND: We aimed to evaluate the efficacy and safety of nab-paclitaxel in patients with refractory advanced non-small cell lung cancer who failed previous chemotherapy. METHODS: Patients were required to have an Eastern Cooperative Oncology Group performance status of 0-2 and adequate organ function. Patients received nab-paclitaxel, 100 mg/m(2) i.v. on days 1, 8, and 15 every 4 weeks. The primary endpoint was the overall response rate. Secondary endpoints were the progression-free survival time, overall survival, and the toxicity profile...
October 16, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29032616/a-survey-on-hematology-oncology-pediatric-aieop-centres-the-challenge-of-posterior-reversible-encephalopathy-syndrome
#3
Daniele Zama, Pietro Gasperini, Massimo Berger, Mariagrazia Petris, Maria D De Pasquale, Simone Cesaro, Maria E Guerzoni, Elena Mastrodicasa, Francesca Savina, Ottavio Ziino, Valentina Kiren, Paola Muggeo, Rosa M Mura, Fraia Melchionda, Giulio A Zanazzo
Posterior reversible encephalopathy syndrome (PRES) is one of the most common neurological complications in hematology-oncology pediatric patients. Despite an increasingly recognized occurrence, no clear consensus exists regarding how best to manage the syndrome, because most cases of PRES have reported in single case reports or small series. Aim of this paper is to identify incidence, clinical features, management and outcome of PRES in a large series of hematology-oncology pediatric patients METHODS: The cases of PRES occurred in twelve centres of the Italian Association of Pediatric Haematology and Oncology were reported RESULTS: 124 cases of PRES in 112 pediatric patients were recorded with an incidence of 2...
October 15, 2017: European Journal of Haematology
https://www.readbyqxmd.com/read/29031507/-sport-coaching-for-psychological-and-social-recovery-after-hematological-cancer-an-innovative-perspective
#4
Sarah Calvin, Didier Blaise, Patrick Ben Soussan, Sarah Cuvelier, Nicolas Cicut, Laurence Caymaris, Yolande Arnault, Claude Onesta, Pierre Dantin, Patrice Viens
This study is a first step towards the transfer of knowledge and practices between psychological support and performance in elite sport and a patient's "social recovery" in oncology. This proposal brings together people engaged in a variety of healthcare and relationship support roles, and aims to set up a support system beyond the hospital context. It questions the ability of elite sport management and its main actors, the "Great Coaches", to contribute to the support of patients in cancer remission through an onco-coaching approach...
October 11, 2017: Bulletin du Cancer
https://www.readbyqxmd.com/read/29028642/-lost-to-follow-up-among-adult-cancer-survivors
#5
Amitoj Gill, Rohit Gosain, Shruti Bhandari, Rahul Gosain, Gurkirat Gill, Joseph Abraham, Kenneth Miller
BACKGROUND: Follow-up cancer care is important for patients who have received IV chemotherapy but some patients discontinue their care and are lost to follow-up (LFU) at the cancer center where they were treated. The purpose of this study was to determine what proportion of cancer survivors are LFU at 5 years after treatment, the timing of LFU, and the characteristics of those who do not continue survivorship care. METHODS: Adult patients with cancer who were treated with chemotherapy at a large community teaching hospital in 2006 and 2007 were identified and linked with State tumor registry data...
October 12, 2017: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29025266/the-abcs-of-immunotherapy-for-adult-patients-with-b-cell-acute-lymphoblastic-leukemia
#6
Troy Z Horvat, Amanda N Seddon, Adebayo Ogunniyi, Amber C King, Larry W Buie, Ryan J Daley
OBJECTIVE: To review the pharmacology, efficacy, and safety of Food and Drug Administration approved and promising immunotherapy agents used in the treatment of acute lymphoblastic leukemia (ALL). DATA SOURCES: A literature search was performed of PubMed and MEDLINE databases (1950 to July 2017) and of abstracts from the American Society of Hematology and the American Society of Clinical Oncology. Searches were performed utilizing the following key terms: rituximab, blinatumomab, inotuzumab, ofatumumab, obinutuzumab, Blincyto, Rituxan, Gazyva, Arzerra, CAR T-cell, and chimeric antigen receptor (CAR)...
October 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/29016837/multicenter-pilot-study-of-radio-chemotherapy-as-first-line-treatment-for-adults-with-medulloblastoma-noa-07
#7
Dagmar Dagmar, Martin Proescholdt, Christiane Reinert, Torsten Pietsch, David T W Jones, Stefan M Pfister, Elke Hattingen, Clemens Seidel, Linda Dirven, Ralf Luerding, Jaap Reijneveld, Monika Warmuth-Metz, Matteo Bonsanto, Michael Bremer, Stephanie Combs, Stefan Rieken, Ulrich Herrlinger, Holger Kuntze, Regine Mayer-Steinacker, Dag Moskopp, Thomas Schneider, Andreas Beringer, Uwe Schlegel, Walter Stummer, Helmut Welker, Astrid Weyerbrock, Frank Paulsen, Stefan Rutkowski, Michael Weller, Wolfgang Wick, Rolf-Dieter Kortmann, Ulrich Bogdahn, Peter Hau
Background: Medulloblastoma in adult patients is rare, with 0.6 cases per million. Prognosis depends on clinical factors and medulloblastoma entity. No prospective data on the feasibility of radio-chemotherapy exist. The German Neuro-Oncology Working Group (NOA) performed a prospective descriptive multicenter single-arm Phase II trial to evaluate feasibility and toxicity of radio-polychemotherapy. Methods: The NOA-07 trial combined cranio-spinal irradiation with vincristine, followed by eight cycles of cisplatin, lomustine and vincristine...
August 21, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/29016568/the-availability-of-jobs-in-the-biopharmaceutical-industry-is-45-fold-greater-for-hematology-oncology-than-medical-specialties
#8
V Kaestner, V Prasad
No abstract text is available yet for this article.
September 15, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28994864/tunisian-adult-s-hodgkin-lymphoma-study-group
#9
Raihane Ben Lakhal, Sondos Hdiji, Yosra Ben Youssef, Mohamed Adnène Laariri, Sami Zriba, Nabil Toumi, Amina Mokrani, Faten Ezzaier, Salwa Ladb, Hatem Frikha, Taha Mesai, Hanen Ben Salah, Sameh Tebra, Jamel Daoued, Noureddine Bouaouina, Monji Maalej, Mounir Frikha, Slim Ben Ahmed, Amel Mezlini, Tarek Ben Othmen, Fehmi Msaddek, Abderrahim Khelif, Moez Elloumi, Balkis Meddeb
The Tunisian adult's Hodgkin lymphoma (HL) Study Group was created in 1999. It aimed to improve the management of this curable hematologic malignancy by standardizing the diagnosis, assessment of disease, treatment management and therapeutic evaluation in different Tunisian centers (Hematology, oncology and radiotherapy).Since 1998, four versions of the prospective national protocol for treating adult Hodgkin lymphoma have succeeded (MDH99, MDH2002, MDH2008, MDH2015). Each version was based on the results of the previous version and analyzed according to new data from the literature...
November 2016: La Tunisie Médicale
https://www.readbyqxmd.com/read/28991126/successful-treatment-of-invasive-conidiobolus-infection-during-therapy-for-acute-lymphoblastic-leukemia
#10
Craig Erker, Anna R Huppler, Thomas J Walsh, Michael E McCormick, Mariko Suchi, Neel S Bhatt, Susan C Kehl, Jessica Southwood, Paul Harker-Murray
Invasive fungal infections are a serious cause of morbidity and mortality in patients with hematologic malignancies. Conidiobolus species are molds within the order Entomophthorales and may disseminate to become rapidly fatal in immunocompromised individuals. This species of fungal infections are often multidrug resistant (MDR) and present unique therapeutic challenges. Reports of Conidiobolus infections are rare in pediatric oncology. We report the successful treatment of an adolescent male with B-cell lymphoblastic leukemia and MDR invasive sinopulmonary Conidiobolus infection with emphasis on early and aggressive neutrophil support with surgical debridement...
October 17, 2017: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/28988692/the-survey-on-cellular-and-tissue-engineered-therapies-in-europe-and-neighboring-eurasian-countries-in-2014-and-2015
#11
Hilary Ireland, Max H P Gay, Helen Baldomero, Barbara De Angelis, Hossein Baharvand, Mark W Lowdell, Jakob Passweg, Ivan Martin
BACKGROUND AIMS: With the support of five established scientific organizations, this report, the seventh of its kind, describes activity in Europe for the years 2014 and 2015 in the area of cellular and tissue-engineered therapies, excluding hematopoietic stem cell (HSC) treatments for the reconstitution of hematopoiesis. METHODS: In 2015 [respectively 2014], 205 [276] teams from 32 countries responded to the cellular and tissue-engineered therapy survey; 178 [126] teams reported treating 3686 [2665] patients...
October 4, 2017: Cytotherapy
https://www.readbyqxmd.com/read/28983382/refeeding-syndrome-in-oncology-report-of-four-cases
#12
Martin Windpessl, Beate Mayrbaeurl, Christian Baldinger, Gernot Tiefenthaller, Friedrich C Prischl, Manfred Wallner, Josef Thaler
The term refeeding syndrome (RFS) refers to the metabolic perturbations and its attendant complications in subjects who are refed after fasting. The syndrome is characterized by profound shifts of electrolytes and fluids. Its consequences are widespread and sometimes fatal. Patients with malignancies are especially vulnerable due to the presence of multiple comorbidities. We report the course of four patients with malignant or hematological disorders who developed RFS while being treated for their underlying illness...
February 2017: World Journal of Oncology
https://www.readbyqxmd.com/read/28982637/pediatric-chronic-patients-at-outpatient-clinics-a-study-in-a-latin-american-university-hospital
#13
Renata A Alveno, Caroline V Miranda, Caroline G Passone, Aurora R Waetge, Elza S Hojo, Sylvia C L Farhat, Vicente Odone-Filho, Uenis Tannuri, Werther B Carvalho, Magda Carneiro-Sampaio, Clovis A Silva
OBJECTIVE: To describe the characteristics of children and adolescentes with chronic diseases of outpatient clinics at a tertiary university hospital. METHODS: A cross-sectional study was performed with 16,237 patients with chronic diseases followed-up in one year. The data were collected through the electronic system, according to the number of physician appointments in 23 pediatric specialties. Patients were divided in two groups: children (0-9 years) and adolescents (10-19 years)...
October 2, 2017: Jornal de Pediatria
https://www.readbyqxmd.com/read/28980601/-the-clinical-observation-of-nk-t-cell-lymphoma-of-the-nasal-type
#14
A B Turovsky, N A Shostak, M E Artemyev, N K Khuazheva, T P Bessarab, P L Chumakov, A V Artemieva-Karelova
The objective of the present work was to present the results of the clinical analysis of the patient presenting with natural killer (NK)/T-cell lymphoma of the nasal type. We undertook the analysis of the medical documentation concerning the case of interest. It was shown that the development of progressive perforation of the nasal septum and the pronounced destructive changes in the intranasal and adjacent structures following the endonasal surgical interventions made necessary differential diagnostics between the condition under consideration and certain latent disorders (such as Wegener's granulomatosis, leprosy, syphilis, leishmaniasis, dirofilariasis tuberculosis, etc...
2017: Vestnik Otorinolaringologii
https://www.readbyqxmd.com/read/28978832/clinical-sequencing-in-leukemia-with-the-assistance-of-artificial-intelligence
#15
Arinobu Tojo
Next generation sequencing (NGS) of cancer genomes is now becoming a prerequisite for accurate diagnosis and proper treatment in clinical oncology. Because the genomic regions for NGS expand from a certain set of genes to the whole exome or whole genome, the resulting sequence data becomes incredibly enormous and makes it quite laborious to translate the genomic data into medicine, so-called annotation and curation. We organized a clinical sequencing team and established a bidirectional (bed-to-bench and bench-to-bed) system to integrate clinical and genomic data for hematological malignancies...
2017: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/28978174/comparison-of-outcomes-between-trimodal-therapy-and-radical-cystectomy-in-muscle-invasive-bladder-cancer-a-propensity-score-matching-analysis
#16
Yeon Joo Kim, Sang Jun Byun, Hanjong Ahn, Choung-Soo Kim, Beom-Sik Hong, Sangjun Yoo, Jae-Lyun Lee, Young Seok Kim
Although radical cystectomy (RC) is considered as the standard therapy for muscle-invasive bladder cancer (MIBC), trimodal therapy (TMT) combining transurethral resection of the tumor with radiotherapy and chemotherapy is increasingly recommended as an alternative approach for bladder preservation. In the absence of randomized trials, we compared the clinical outcomes between RC and TMT using propensity score matching with 50 patients in the RC arm and 29 patients in the TMT arm. With respective median follow-up periods of 23 and 32 months for the RC and TMT groups, 5-year distant metastasis-free survival (58% vs...
September 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28976120/tumor-molecular-profiling-in-the-treatment-of-refractory-cancers-%C3%A2
#17
Birendra Kc, Muhammad Zubair Afzal, Andrew Sochaki, Katherine A Wentland, Rubens Chang, Sudhir Singh, Timothy O'Rourke
INTRODUCTION: Molecular profiling (MP) has been used as a technique to identify treatment regimens for individual patient's cancer. The results of MP has been used to guide targeted therapy specific to each patient's tumor that resulted in a longer progression free survival (PFS) compared to the last conventional treatment. This study aims to provide further data to delineate the PFS of patients who get treated with targeted therapy based on MP. METHODS: A retrospective chart review was performed...
September 2017: Journal of Experimental Therapeutics & Oncology
https://www.readbyqxmd.com/read/28971174/investigation-of-celiac-disease-followed-by-immune-thrombocytopenic-purpura-diagnosis-in-patients-and-comparison-with-literature
#18
Hakan Sarbay, Halil Kocamaz, Mehmet Akin, Bayram Ozhan
OBJECTIVE: Celiac disease (CD) and Immune thrombocytopenic purpura (ITP) may occur together as a result of similar autoimmune mechanisms. The aim of this study was to assess the frequency of CD in a group of ITP patients and in the literature. METHODS: A total of 29 patients in Pamukkale University Faculty of Medicine Hospital Pediatric Hematology and Oncology Department with ITP were included in the study. Test was performed for the antibodies related to CD. Positive result for celiac antibodies was confirmed with biopsy...
2017: Northern Clinics of Istanbul
https://www.readbyqxmd.com/read/28970685/therapeutic-leukocyte-reduction-for-acute-and-chronic-myeloid-leukemias-a-4-year-experience-from-an-oncology-center-in-india
#19
Anita A Tendulkar, Puneet A Jain, Abhaykumar Gupta, Nidhi Sharma, Anisha Navkudkar, Vijaya Patle
INTRODUCTION: Hyperleukocytosis (HL) and leukostasis seen in myeloid leukemias are a medical emergency. We present a case series of ten such patients in a 4-year period. Sixteen therapeutic leukocyte reduction (TLR) were done in ten cases along with other supportive measures. The American Society for Apheresis supports the routine implementation of TLR in cases of HL secondary to myeloid leukemias with signs of leukostasis. MATERIALS AND METHODS: The procedures were performed on the intermittent flow cell separator after discussion with the treating physician about patient's condition...
July 2017: Asian Journal of Transfusion Science
https://www.readbyqxmd.com/read/28968172/modernizing-clinical-trial-eligibility-criteria-recommendations-of-the-american-society-of-clinical-oncology-friends-of-cancer-research-organ-dysfunction-prior-or-concurrent-malignancy-and-comorbidities-working-group
#20
Stuart M Lichtman, R Donald Harvey, Marie-Anne Damiette Smit, Atiqur Rahman, Michael A Thompson, Nancy Roach, Caroline Schenkel, Suanna S Bruinooge, Patricia Cortazar, Dana Walker, Louis Fehrenbacher
Purpose Patients with organ dysfunction, prior or concurrent malignancies, and comorbidities are often excluded from clinical trials. Excluding patients on the basis of these factors results in clinical trial participants who are healthier and younger than the overall population of patients with cancer. Methods ASCO and Friends of Cancer Research established a multidisciplinary working group that included experts in trial design and conduct to examine how eligibility criteria could be more inclusive. The group analyzed current eligibility criteria; conducted original data analysis; considered safety concerns, potential benefits, research, and potential hurdles of this approach through discussion; and reached consensus on recommendations regarding updated eligibility criteria that prioritize inclusiveness without compromising patient safety...
October 2, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
keyword
keyword
97492
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"